FindTrial
Sign In

A study to evaluate post COVID-19 lung damage.

A retrospective study to evaluate clinical and radiological course in COVID 19 interstitial pneumonia.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/029437
Enrollment
300
Registered
2020-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: NIL: NIL

Sponsors

Medanta Institute of Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients confirmed with COVID-19, admitted to Medanta-The Medicity, Gurgaon, India. 2. Patients with moderate or severe COVID 19 pneumonia, admitted to ward or ICU.

Exclusion criteria

Exclusion criteria: 1. Age 2. Patients with mild COVID 19 3. Pregnant female 4. Patients with history of COVID-19 Interstitial Pneumonia treatment

Design outcomes

Primary

MeasureTime frame
High-resolution computed tomography (HRCT) features of COVID 19 at presentation and 12 weeks later Timepoint: High-resolution computed tomography (HRCT) features of COVID 19 at presentation and 12 weeks later—

Secondary

MeasureTime frame
Effect of therapy used Role of anti-fibrotic medications Pulmonary Function Test: Spirometry Blood tests-complete blood count, coagulopathy studies, D-dimers, Ferritin, CRP, comprehensive metabolic panel to include electrolytes, liver and renal function testsTimepoint: 12 WEEKS—

Countries

India

Contacts

Public ContactDr Bornali Datta

Medanta The Medicity Gurugram Haryana India

bornalidatta@googlemail.com9818462626

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026